YSB (09885) rose more than 7% in late trading. At the time of writing, the stock was up 6.86% to HK$5.6, with a turnover of HK$33.9543 million. On the news front, according to the latest equity disclosure from the Hong Kong Stock Exchange on March 30, Zhang Buzhen, Chairman and CEO of YSB, increased his stake in the company by 200,000 ordinary shares through affiliated entity MIYT Holdings Limited on March 26, 2026, at an average price of HK$5.3114 per share, involving approximately HK$1.0623 million. Following this purchase, the shareholding percentage of MIYT Holdings Limited increased from 18.29% to 18.32%. Notably, this marks the first market purchase by founder Zhang Buzhen since the company's listing. China Securities (CSC) pointed out that in 2025, YSB achieved operating revenue of RMB 20.97 billion, a year-on-year increase of 17.1%, net profit attributable to shareholders of RMB 153 million, up 409.7% year-on-year, and an adjusted net profit of RMB 237 million, an increase of 51.2% year-on-year, with performance meeting the institution's previous expectations. The company operates as an integrated online platform for pharmaceuticals and healthcare. Looking ahead to 2026, YSB continues to accelerate the growth of its self-operated business, including proprietary brands and exclusive cooperative products, with gross profit margin expected to improve steadily. It is also expanding into sectors such as POCT devices and instant retail, aiming to achieve synergy across healthcare, pharmaceuticals, and testing, signaling that its diversified businesses are entering a harvest period.